211 related articles for article (PubMed ID: 22348983)
1. Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis.
Eastell R; Reid DM; Vukicevic S; Ensrud KE; LaCroix AZ; Thompson JR; Thompson DD; Cummings SR
Bone; 2012 May; 50(5):1135-40. PubMed ID: 22348983
[TBL] [Abstract][Full Text] [Related]
2. A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy.
Rogers A; Glover SJ; Eastell R
Bone; 2009 Dec; 45(6):1044-52. PubMed ID: 19665601
[TBL] [Abstract][Full Text] [Related]
3. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
4. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
Chen P; Satterwhite JH; Licata AA; Lewiecki EM; Sipos AA; Misurski DM; Wagman RB
J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
[TBL] [Abstract][Full Text] [Related]
5. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
6. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
7. Effects of lasofoxifene on bone in surgically postmenopausal cynomolgus monkeys.
Lees C; Shen V; Brommage R
Menopause; 2007; 14(1):97-105. PubMed ID: 17075430
[TBL] [Abstract][Full Text] [Related]
8. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
9. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
[TBL] [Abstract][Full Text] [Related]
10. Correlations of serum prolidase activity between bone turnover markers and mineral density in postmenopausal osteoporosis.
Verit FF; Geyikli I; Yazgan P; Celik A
Arch Gynecol Obstet; 2006 Jun; 274(3):133-7. PubMed ID: 16532321
[TBL] [Abstract][Full Text] [Related]
11. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
12. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
[TBL] [Abstract][Full Text] [Related]
13. Reference intervals of biochemical bone turnover markers for Saudi Arabian women: a cross-sectional study.
Ardawi MS; Maimani AA; Bahksh TA; Rouzi AA; Qari MH; Raddadi RM
Bone; 2010 Oct; 47(4):804-14. PubMed ID: 20659600
[TBL] [Abstract][Full Text] [Related]
14. PINP as an aid for monitoring patients treated with teriparatide.
Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
[TBL] [Abstract][Full Text] [Related]
15. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
16. Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.
Ensrud K; LaCroix A; Thompson JR; Thompson DD; Eastell R; Reid DM; Vukicevic S; Cauley J; Barrett-Connor E; Armstrong R; Welty F; Cummings S
Circulation; 2010 Oct; 122(17):1716-24. PubMed ID: 20937977
[TBL] [Abstract][Full Text] [Related]
17. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
18. Lasofoxifene in osteoporosis and its place in therapy.
Swan VJ; Hamilton CJ; Jamal SA
Adv Ther; 2010 Dec; 27(12):917-32. PubMed ID: 21080249
[TBL] [Abstract][Full Text] [Related]
19. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
20. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
